FOR IMMEDIATE RELEASE   AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Achieved record Feraheme revenue growth and more than 50% market share for Makena auto-injector Completed integration of Perosphere Pharmaceuticals Inc. and progressed ciraparantag clinical program Reaffirms 2019 financial guidance Conference call scheduled for 8:00 a.m. ET today   WALTHAM,… More

WALTHAM, Mass. May 3, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it will present new data related to investigational drug bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) and Feraheme® (ferumoxytol) related to iron deficiency anemia (IDA) resulting from abnormal uterine bleeding (AUB) at the American College of Obstetricians and Gynecologists… More

FOR IMMEDIATE RELEASE AMAG Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019 at 8:00 a.m. ET   WALTHAM, Mass., April 30, 2019 –  AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its first quarter 2019 financial results will be released on Tuesday, May 7, 2019 before… More

AMAG PHARMACEUTICALS ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(c)(4) WALTHAM, Mass., April 30, 2019 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 15,000 shares of common stock and (ii) 7,500 restricted stock units. The option will have… More

WALTHAM, Mass., April 16, 2019 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Nancy Griffith, Ph.D., as vice president, scientific communications and medical operations, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Griffith will be responsible for the creation and implementation of AMAG’s medical communications and publication strategies. “As AMAG continues to invest in development-stage assets… More

WALTHAM, Mass. April 12, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the election of two new members to its Board of Directors—Anne Phillips, M.D., senior vice president, clinical development, medical and regulatory affairs for Novo Nordisk, Inc. and Kathrine O’Brien, former vice president and general manager, skin and marketing services for Unilever PLC. In… More

AMAG Pharmaceuticals to Present at Needham 18th Annual Healthcare Conference WALTHAM, Mass., April 2, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Ted Myles, chief financial officer, will present at the Needham 18th Annual Healthcare Conference in New York City on Tuesday, April 9, 2019 at 4:10 p.m. A live audio webcast will be… More

MARCH OF DIMES AND AMAG PHARMACEUTICALS, INC., ANNOUNCE FIRST JOINT SUPPORTIVE PREGNANCY CARE PROGRAM  First Site Launches in Springfield, Mass. Offering an Innovative Model of Group Prenatal Care ARLINGTON, VA and WALTHAM, Mass. March 20, 2019 — March of Dimes and AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced Baystate Medical Center’s Wesson Women’s Clinic in Springfield,… More

WALTHAM, Mass. March 8, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena® in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted as part of an approval commitment under the Food… More

WALTHAM, Mass. March 7, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that new and encore data related to bremelanotide and Hypoactive Sexual Desire Disorder (HSDD) will be presented at the upcoming International Society for the Study of Women’s Sexual Health (ISSWSH)/ International Society for Sexual Medicine (ISSM) Joint meeting taking place in Atlanta, Georgia… More